The market reaction reflects that China accounted for roughly 14–20% of ASML's recent revenue, and DUV immersion tools are a meaningful slice of those sales . A credible domestic competitor — even at very early stages — raises the question of whether ASML's monopoly in DUV lithography is eroding.
BofA called the sell-off an "overreaction" and reiterated its Buy rating with a $2,845 price target on ASML's U.S.-listed shares .
On this specific sell-off, JPMorgan's detailed post-report assessment is not as widely cited as BofA's, but the bank's broader view came through in earlier and related coverage.
BNP Paribas joined BofA and JPMorgan in describing the sell-off as excessive, citing four structural reasons .
| Factor | BofA | JPMorgan | BNP Paribas |
|---|---|---|---|
| Rating / Stance | Buy, $2,845 PT, sell-off is "overreaction" | Cautious but sees limited near-term threat | Sell-off excessive, moat intact |
| China production (2026/27) | ~5 / ~20 units | Same figures, negligible vs. ASML | ~5 / ~20, tiny relative to ASML's ~130 |
| Revenue impact | Modest threat, no material near-term impact; max €1.4B (2.4% of sales) | Minimal from domestic replacement; bigger risk from U.S. export curbs | Not material at current scale |
| Technological gap | Significant lag in precision, throughput, reliability | "Far to go to match ASML" | Huge gap in precision, throughput, supply chain |
| Key differentiator | EUV monopoly is the true moat; China can't access it | Long-term self-sufficiency story, not near-term risk | Proprietary tech and supply chains are hard to replicate |
Bottom line: All three banks see the Chinese DUV breakthrough as real but dramatically overhyped by the market. The consensus is that the reported volumes are a rounding error compared to ASML's production scale, the technological gap remains wide, and ASML's EUV monopoly — which China cannot legally access — provides a structural moat that DUV competition alone cannot breach.